GlaxoSmithKline will soon release their most recent version of MyAsthma, an app for asthma patients.
According to PMLive, “The new version of MyAsthma, which will be made more widely available from early 2017, is the first time a mobile app from pharma has been approved as a Class 1 medical device and CE marked […] The original version of MyAsthma was not a medical device, but the new version entered that territory by providing a customised view to the user through the provision of contexualised content.”
The app, which was created with healthcare professionals, allows patients gain more awareness of how the environment affects their symptoms. The app includes an Asthma Control Test, a clinically validated questionnaire that allows users to see how well their asthma is being controlled based on their answers over the past four months.
The MyAsthma app also allows users to input information such as when and where asthma attacks happen, whether or not an inhaler was used and what happened during the attack. If users see that attacks occur during certain weather conditions, they can better identify triggers for attacks.
Other app features include:
- Storing Peak Flow results
- Recording exercise results and other health-tracking applications
- haring results with doctors
- Medication reminders
- Appointment tracking
- Record sleep and mood informat
- Ability to automatically store additional wearable fitness device information
- Storing information for others such as a child’s information